GlassScriptPhysician profile
Cynthia Chow
NPI 1063093102
$990.99
in general payments reported to CMS, 2019-2025
18 companies · $726 in 2025
The $726 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $265 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $218.29 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $192.16 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.28 | 2024-2025 | Caplyta |
| Dexcom, INC. | $86.68 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $70.76 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.73 | 2024-2025 | Xifaxan |
| Abbvie INC. | $55.42 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $48.04 | 2024-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $17.85 | 2025 | Zoryve |
| Antares Pharma, INC. | $17.30 | 2025 | Xyosted |
| Nevro Corp. | $15.70 | 2024 | Senza |
| Astellas Pharma US INC | $15.29 | 2024 | Veozah |
| Hologic Sales and Service, LLC | $14.73 | 2024 | Aptima, Thinprep 2000 Processor |
| Alexion Pharmaceuticals, INC. | $14.68 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $14.32 | 2024 | Gardasil, Gardasil 9, Capvaxive |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.12 | 2025 | Jardiance |
| Alkermes, INC. | $13.92 | 2024 | Vivitrol |
| Amgen INC. | $13.72 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.